Germantown: Precigen, Inc., a biopharmaceutical company specializing in the advancement of innovative precision medicines to ...

Zopapogene imadenovec is a non-replicating adenoviral vector-based immunotherapy designed to induce an immune response against HPV 6 and HPV 11 proteins.

Precigen, Inc., a biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the ...

Precigen's Papzimeos wins FDA approval as the first therapy for adult recurrent respiratory papillomatosis, showing durable results in clinical trials.

The US Food and Drug Administration (FDA) has approved Papzimeos (zopapogene imadenovec-drba) for the treatment of adults ...

Papzimeos is the first and only FDA-approved treatment for adults with recurrent respiratory papillomatosis (RRP), with ...

A calm hobby quickly shifted into an unexpected challenge, proving that even soothing pastimes can surprise you.

The FDA approved the adenoviral vector-based immunotherapy, zopapogene imadenovec-drba, for treatment of certain patients ...

Precigen (PGEN) stock jumps as the FDA approves the company's gene therapy Papzimeos for adults with recurrent respiratory ...

Papzimeos is the first immunotherapy approved for recurrent respiratory papillomatosis, a rare lung disorder involving the ...

Precigen's immunotherapy for a rare respiratory disease has become the first treatment to win U.S. regulatory approval for ...